STE
SterisNYSEHealth CareMedical DevicesSnapshot 2026-05-08
As of May 8, 2026, STE has a composite score of 20.6 and a signal label of "mild favorable." This score is influenced by a medium confidence level of 74.9, with strengths in management (60.4) and quality (64.2), while the sector score is low at 7.6. The analysis is provisional, indicating that the scores and assessments may change as new information becomes available.
Price
Daily closes from AlphaVantage. Earnings/event dots are placed inline.
Factor signals
Read top-to-bottom: thesis (is this a strong company over a 1–3 year hold), watch flags (has something changed worth re-reading), and position context (how violent might the path be). Each pill is a parallel diagnostic — never aggregated into a single score.
Thesis
— is this a strong company over a 1–3 year hold?Why this rank
- Direction share1.00
- Slope (norm)0.12
- Bonus0.00
Why this rank
Trailing four: 2025-Q3, 2026-Q1, 2026-Q2, 2026-Q3
Why this rank
Joint read: strong + robust historically delivered 80%+ NI-grew rate over T+1y in IT 2024–26 (small N).
Watch
— has something changed worth re-reading?Why this setup
EPS estimate $2.51 → $2.49 (-0.8% / 30d). 2 raised, 4 cut, 6 covering analysts.
0 upgrades, 0 downgrades / 30d. 63% of analysts rate Buy.
0 positive, 0 negative / 30d.
F4 · Management deep-dive — recent events, stated priorities, guidance track record
Recent 8-K events
5 material events in the last 24 months — top 5 listed below.
Stated priorities
3 priorityies extracted from earnings transcripts (as of 2026-05-08).
- 1.Increase revenue by 8-9% in fiscal 2026growthon track93% progressprovisional
2/4: “For fiscal 2026, the Company expects as reported revenue from continuing operations to increase 8-9%.”
Why this status
Stated in 3 of last 3 quarters. Revenue grew from $1.279B in 2025-Q1 to $1.496B in 2026-Q3, indicating progress towards the 8-9% growth target for fiscal 2026. The trajectory is delivering on management's stated priority.
- 2.Achieve $850M free cash flow in fiscal 2026capital allocationmixed65% progressprovisional
2/4: “Free cash flow is expected to be approximately $850 million.”
Why this status
Stated in 3 of last 3 quarters. Cash from operating activities was $1.006B in 2026-Q3, supporting the $850M free cash flow target for fiscal 2026. The trajectory is delivering on management's stated priority.
- 3.Maintain capital expenditures at $375Mcapital allocationmixed65% progressprovisional
2/4: “Capital expenditures are anticipated to be approximately $375 million.”
Why this status
Stated in 3 of last 3 quarters. Management has consistently guided capital expenditures to be approximately $375 million for fiscal 2026. The financials do not provide specific capex figures, but the consistent guidance indicates a stable capital allocation strategy.
Guidance track record
Insufficient guidance history for this ticker.
Position context
— how violent might the path be while I hold it?Why this risk level
Recent vol — 30d annualized 23%; 252d 25%.
Drawdown — Max 1y −23%. Bad day move −2%.
Beta to sector ETF (XLV) — 0.70 over 1y.
Liquidity — score 100/100.
Sub-scores — vol 59/100, drawdown 55/100, beta 70/100, earnings vol —.
via XLV
Tailwind = sector leading the S&P 500; headwind = trailing. Both can be constructive — historically, headwind regimes have averaged stronger forward returns than tailwind.
Context label only — describes the market state (e.g. real bear vs narrative panic, healthy uptrend vs late-stage froth). It is not a per-ticker buy/sell signal and does not predict factor performance.
Not investment advice. As of 2026-05-08.
What changed
The most important moves since the prior daily snapshot.
- No material changes since the prior snapshot.
No material changes since the prior snapshot.
as of 2026-05-08
Management scorecard
How management runs the business — capital, margins, balance sheet, and how reliably they guide and deliver.
What management is focused on
Priorities management has stated in recent disclosures, with status and evidence drawn from earnings calls, filings, and press releases.
- #1
Increase revenue by 8-9% in fiscal 2026
GrowthManagement aims to achieve an 8-9% increase in revenue for fiscal 2026.
On trackStated in 3 of last 3 quarters. Revenue grew from $1.279B in 2025-Q1 to $1.496B in 2026-Q3, indicating progress towards the 8-9% growth target for fiscal 2026. The trajectory is delivering on management's stated priority.
93%CEO/CFO:“For fiscal 2026, the Company expects as reported revenue from continuing operations to increase 8-9%.”Multiple sourcesSource dated 2026-02-04Stated 3 of last 8 quartersFirst seen 2026-02-04provisionalShow history (3)
- 2026-Q3Multiple sources
“For fiscal 2026, the Company expects as reported revenue from continuing operations to increase 8-9%.”
- 2026-Q2Multiple sources
“For fiscal 2026, the Company expects as reported revenue from continuing operations to increase 8-9%, unchanged from prior outlook.”
- 2026-Q1Multiple sources
“For fiscal 2026, the Company now expects as reported revenue from continuing operations to increase 8-9%.”
- #2
Achieve $850M free cash flow in fiscal 2026
Capital allocationManagement aims to achieve approximately $850 million in free cash flow for fiscal 2026.
MixedStated in 3 of last 3 quarters. Cash from operating activities was $1.006B in 2026-Q3, supporting the $850M free cash flow target for fiscal 2026. The trajectory is delivering on management's stated priority.
65%CEO/CFO:“Free cash flow is expected to be approximately $850 million.”Multiple sourcesSource dated 2026-02-04Stated 3 of last 8 quartersFirst seen 2026-02-04provisionalShow history (3)
- 2026-Q3Multiple sources
“Free cash flow is expected to be approximately $850 million.”
- 2026-Q2Multiple sources
“Free cash flow is now expected to be approximately $850 million, an increase from prior expectations of $820 million.”
- 2026-Q1Multiple sources
“Free cash flow is now expected to be approximately $820 million, an increase from prior expectations of $770 million.”
- #3
Maintain capital expenditures at $375M
Capital allocationManagement plans to maintain capital expenditures at approximately $375 million for fiscal 2026.
MixedStated in 3 of last 3 quarters. Management has consistently guided capital expenditures to be approximately $375 million for fiscal 2026. The financials do not provide specific capex figures, but the consistent guidance indicates a stable capital allocation strategy.
65%CEO/CFO:“Capital expenditures are anticipated to be approximately $375 million.”Multiple sourcesSource dated 2026-02-04Stated 3 of last 8 quartersFirst seen 2026-02-04provisionalShow history (3)
- 2026-Q3Multiple sources
“Capital expenditures are anticipated to be approximately $375 million.”
- 2026-Q2Multiple sources
“Capital expenditures are anticipated to be approximately $375 million.”
- 2026-Q1Multiple sources
“Capital expenditures are anticipated to be approximately $375 million.”
How this stock is priced
Two ways to read price: against peers in the same business, and against the company's own history.
Looks more expensive than peers.
Cheaper than its own typical valuation.
P/E over the last 5 years
71 monthly pointsHow this compares
A side-by-side read on composite, valuation, and risk versus peers.
| Stock | Composite | Valuation | Risk |
|---|---|---|---|
STE Steris | +21 | fair | moderate |
LLY Lilly (Eli) | +21 | full | moderate |
JNJ Johnson & Johnson | +18 | full | low |
ABBV AbbVie | +12 | fair | low |
UNH UnitedHealth Group | +24 | fair | elevated |
Risk — how this stock moves
What a normal day looks like, what a bad day looks like, and the worst the last year has thrown at it.
What could change this view
Conditional scenarios — if X happens, the score would shift by about Y points. These are not predictions.
- If health_care sector trend rises from +0.06 into 'improving' (>= +0.20)+5.0 pts
- If next-quarter guidance is raised (currently NEW as of 2026-02-04)+4.0 pts
- If next-quarter guidance is cut (currently NEW as of 2026-02-04)-8.0 pts
- If labor state reverses from -0.31 (negative) to +0.31 (positive)-6.8 pts
- If health_care sector trend falls from +0.06 into 'weakening' (<= -0.20)-5.0 pts
Material updates
Recent SEC 8-K filings ranked by likely impact, confidence, and recency.
- 2026-05-071d agoItem 5.02
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On May 1, 2026, Richard C. Breeden notified STERIS plc (the “Company”) that he will not stand for reelection to the Board of Directors (the “Board”) at the Company’s 2026 Annual General Meeting of Shareholders. Mr. Breeden’s decision to retire is not the result of any disagreement with the Company on any matters related to the Company’s operations,…
executive changeneutralscore 78 - 2026-04-061mo agoItem 5.02
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On March 31, 2026, STERIS plc (the “Company”) and Michael J. Tokich, the Company’s former Chief Financial Officer, entered into an amendment (the “Amendment”) to the Transition Agreement, dated August 5, 2025, between the Company and Mr. Tokich (the “Agreement”). In general, the Agreement governs the compensation and benefits that Mr. Tokich receiv…
executive changeneutralscore 38 - 2026-02-043mo agoItem 2.02
of this Current Report on Form 8-K, including Exhibit 99.1 attached hereto, is being furnished to the Securities and Exchange Commission and shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, or otherwise subject to the liabilities of that Section. Furthermore, the information contained in this
earnings preannouncementneutralscore 8 - 2025-07-0310mo agoItem 5.02
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On July 1, 2025, Dr. Richard Steeves notified STERIS plc (the “Company”) that he will retire from the Board of Directors (the “Board”) on the date of the Company’s Annual General Meeting of Shareholders (the “Annual Meeting”) to be held on July 31, 2025. Therefore, Dr. Steeves will not stand for re-election to the Board at the Annual Meeting. Dr. S…
executive changeneutralscore 0
Score history
The composite score, snapshot by snapshot. The dotted line at zero separates leaning-positive from leaning-negative.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.